SEARCH

SEARCH BY CITATION

References

  • 1
    Cao Y & Lam L (2003) Bispecific antibody conjugates in therapeutics. Adv Drug Del Rev 55, 171197.
  • 2
    Kufer P, Lutterbuse R & Baeuerle PA (2004) A revival of bispecific antibodies. Trends Biotechnol 22, 238244.
  • 3
    Raso V & Griffin T (1981) Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res 41, 20732078.
  • 4
    Suresh MR, Cuello AC & Milstein C (1986) Bispecific monoclonal antibodies from hybrid hybridomas. Methods Enzymol 121, 210228.
  • 5
    Kriangkum J, Xu B, Nagata LP, Fulton RE & Suresh MR (2001) Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 18, 3140.
  • 6
    Perisic O, Webb PA, Holliger P, Winter G & Williams RL (1994) Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 12171226.
  • 7
    Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M & Little M (1999) A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood 94, 25622568.
  • 8
    Gao Y, Xiong D, Yang M, Liu H, Peng H, Shao X, Xu Y, Xu C, Fan D, Qin L et al. (2004) Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody. Leukemia 18, 513520.
  • 9
    Kipriyanov SM, Cochlovius B, Schafer HJ, Moldenhauer G, Bahre A, Le Gall F, Knackmuss S & Little M (2002) Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin’s lymphoma. J Immunol 169, 137144.
  • 10
    Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z, Fan D, Yang M, Han J, Xie Y et al. (2002) Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Cancer Lett 177, 2939.
  • 11
    Asano R, Takemura S, Tsumoto K, Sakurai N, Teramae A, Ebara S, Katayose Y, Shinoda M, Suzuki M, Imai K et al. (2000) Functional construction of the anti-mucin core protein (MUC1) antibody MUSE11 variable regions in a bacterial expression system. J Biochem (Tokyo) 127, 673679.
  • 12
    Asano R, Kudo T, Nishimura Y, Makabe K, Hayashi H, Suzuki M, Tsumoto K & Kumagai I (2002) Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment. J Biochem (Tokyo) 132, 903909.
  • 13
    Asano R, Sone Y, Makabe K, Tsumoto K, Hayashi H, Katayose Y, Unno M, Kudo T & Kumagai I (2006) Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res 12, 40364042.
  • 14
    Asano R, Sone Y, Ikoma K, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M, Kudo T & Kumagai I (2008) Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Eng Des Sel 21, 597603.
  • 15
    Foote J & Winter G (1992) Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224, 487499.
  • 16
    Vargas-Madrazo E & Paz-Garcia E (2003) An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues. J Mol Recognit 16, 113120.
  • 17
    Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P & Zeillinger R (1997) EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 17, 613619.
  • 18
    Ferrini S, Cambiaggi A, Sforzini S, Marciano S, Canevari S, Mezzanzanica D, Colnaghi MI, Grossi CE & Moretta L (1993) Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation. Int J Cancer 55, 931937.
  • 19
    Pfosser A, Brandl M, Salih H, Grosse-Hovest L & Jung G (1999) Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study. Int J Cancer 80, 612616.
  • 20
    Nagorsen D & Baeuerle PA (2011) Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317, 12551260.
  • 21
    Tsumoto K, Shinoki K, Kondo H, Uchikawa M, Juji T & Kumagai I (1998) Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent – application to a human single-chain Fv fragment. J Immunol Methods 219, 119129.
  • 22
    Jones PT, Dear PH, Foote J, Neuberger MS & Winter G (1986) Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321, 522525.
  • 23
    Riechmann L, Clark M, Waldmann H & Winter G (1988) Reshaping human antibodies for therapy. Nature 332, 323327.
  • 24
    Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP & Waldmann TA (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 86, 1002910033.
  • 25
    Co MS, Deschamps M, Whitley RJ & Queen C (1991) Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A 88, 28692873.
  • 26
    Ohtomo T, Tsuchiya M, Sato K, Shimizu K, Moriuchi S, Miyao Y, Akimoto T, Akamatsu K, Hayakawa T & Ohsugi Y (1995) Humanization of mouse ONS-M21 antibody with the aid of hybrid variable regions. Mol Immunol 32, 407416.
  • 27
    Nakanishi T, Tsumoto K, Yokota A, Kondo H & Kumagai I (2008) Critical contribution of VH-VL interaction to reshaping of an antibody: the case of humanization of anti-lysozyme antibody, HyHEL-10. Protein Sci 17, 261270.
  • 28
    Lu D, Jimenez X, Witte L & Zhu Z (2004) The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody. Biochem Biophys Res Commun 318, 507513.
  • 29
    Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B & Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19 ×  CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 20982103.
  • 30
    Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R et al. (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130, 218228.
  • 31
    Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F et al. (2008) A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J Immunother 31, 871884.
  • 32
    Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, Schwemmlein M, Stein C, Mentz K, Mackensen A et al. (2010) Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16. J Immunother 33, 599608.
  • 33
    Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, Titgemeyer F, Niederweis M, Peipp M, Zunino SJ et al. (2004) A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 125, 167179.
  • 34
    Asano R, Ikoma K, Kawaguchi H, Ishiyama Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T et al. (2010) Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J 277, 477487.
  • 35
    Asano R, Kawaguchi H, Watanabe Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T & Kumagai I (2008) Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells. J Immunother 31, 752761.
  • 36
    Asano R, Ikoma K, Sone Y, Kawaguchi H, Taki S, Hayashi H, Nakanishi T, Umetsu M, Katayose Y, Unno M et al. (2010) Highly enhanced cytotoxicity of a dimeric bispecific diabody, the hEx3 tetrabody. J Biol Chem 285, 2084420849.
  • 37
    Ono K, Ohtomo T, Yoshida K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M & Tsuchiya M (1999) The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol 36, 387395.
  • 38
    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T & Bendig MM (1993) Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53, 851856.
  • 39
    Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T & Bendig MM (1994) Humanization of a mouse anti-human interleukin-6 receptor antibody comparing two methods for selecting human framework regions. Mol Immunol 31, 371381.
  • 40
    Wang X & Stollar BD (1999) Immunoglobulin VH gene expression in human aging. Clin Immunol 93, 132142.
  • 41
    Ramsland PA, Brock CR, Moses J, Robinson BG, Edmundson AB & Raison RL (1999) Structural aspects of human IgM antibodies expressed in chronic B lymphocytic leukemia. Immunotechnology 4, 217229.
  • 42
    Yokota A, Tsumoto K, Shiroishi M, Kondo H & Kumagai I (2003) The role of hydrogen bonding via interfacial water molecules in antigen-antibody complexation. The HyHEL-10-HEL interaction. J Biol Chem 278, 54105418.
  • 43
    Sondermann P & Jacob U (1999) Human Fcgamma receptor IIb expressed in Escherichia coli reveals IgG binding capability. Biol Chem 380, 717721.
  • 44
    Asano R, Ikoma K, Shimomura I, Taki S, Nakanishi T, Umetsu M & Kumagai I (2011) Cytotoxic enhancement of a bispecific diabody by format conversion to tandem single-chain variable fragment (taFv): the case of the hEx3 diabody. J Biol Chem 286, 18121818.
  • 45
    Kabat EA, Wu TT, Perry HM, Gottesman KS & Foeller C (1991) Sequences of Proteins of Immunological Interest, 5th edn. National Institutes of Health, Bethesda, MD.